MRK vs MS: Which Is the Better Buy?
Side-by-side comparison of Merck & Co., Inc. and Morgan Stanley — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-09-18.
Merck & Co., Inc. · Healthcare
$147.17
-4.1% upside to fair value
Med Conviction
Grade C
VS
Morgan Stanley · Financial Services
$206.27
+15.9% upside to fair value
Med Conviction
Grade C
QuantHub Verdict
MS has more upside to fair value
(+15.9%).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
MRK |
MS |
| Current Price |
$147.17 |
$206.27 |
| Fair Value Estimate |
$141.07 |
$239.00 |
| Upside to Fair Value |
-4.1%
|
+15.9%
|
| Market Cap |
$363.5B |
$325.4B |
| Forward P/E |
—
|
—
|
| EV / EBITDA |
29.6x
|
23.5x
|
| Price / Sales |
5.5x
|
2.6x
|
| Price / FCF |
22.6x
|
—
|
| Revenue Growth YoY |
+5.1%
|
+22.4%
|
| Gross Margin |
75.4%
|
59.7%
|
| Operating Margin |
16.7%
|
20.7%
|
| Return on Equity |
6.6%
|
18.1%
|
| Dividend Yield |
2.31% |
2.01% |
| FCF Yield |
4.42%
|
—
|
| Analyst Consensus |
Buy
|
Hold
|
Investment Thesis
Merck & Co., Inc. is a global healthcare leader with two core divisions, Pharmaceuticals and Animal Health, spanning oncology, vaccines, acute hospital care, immunology, neuroscience, virology, cardiovascular and diabetes, and it employs roughly 74,000 people under CEO Robert Davis. The business quality is medium: TTM gross margin of 75.4% and TTM operating margin of 16.7% reflect a genuinely hig…
Morgan Stanley is a diversified capital-markets and wealth-management franchise spanning institutional securities, advisor-led and self-directed wealth, workplace services, and investment management. Business quality is solid but inherently cyclical: it combines $8.084 trillion of wealth client assets and $2.004 trillion of investment-management AUM/AUS with a strengthening 15.5% institutional pe…
Accumulation Zones
| Metric |
MRK |
MS |
| Zone Low |
$105.80 |
$179.25 |
| Zone High |
$119.91 |
$203.15 |
| In Buy Zone? |
No
|
No
|